Skip to content

Speaker Interview – ViaCyte

Exclusive Interview

An Interview With:

EPB headshot July 2019

Eugene Brandon
Senior Director of Strategic Relations
ViaCyte

How and to what capacity is ViaCyte involved with developing cell therapies for diabetes?

 

ViaCyte is a leader in the field in advancing stem cell-derived islet replacement therapies for insulin-requiring diabetes.

We were the first to demonstrate directed differentiation of human pluripotent stem cells into pancreatic endoderm cells and show that these cells produce insulin in response to increased blood glucose. ViaCyte was also first to validate in preclinical and clinical studies that these cells can further differentiate in vivo to the constituent cell types of the pancreatic islet.

 

"Our technology platforms have the potential to yield treatments for other diseases, especially those that are caused by a loss or malfunction of a specific cell or tissue type"